In this 2016 randomized, controlled prospective study of 192 adults with autoimmune thyroiditis, patients were given either 83 mcg SeMet daily or no treatment for four months. At the end of the study, 31.3% of patients in the SeMet group had restored euthyroidism (TSH <4.5mUI/L) compared to 3.1% of patients in the control group. References: …
This 2020 follow up RCT study from Pirola et al. assessed thyroid function in 50 patients with subclinical hypothyroidism due to Hashimoto’s thyroiditis. Subjects receiving 83 mch of selenomethionine daily were assessed for TSH levels, TPO Ab over four months. Results showed a normalization of serum TSH levels in 50% of subjects which was maintained …
A double-blind, placebo-controlled clinical trial from 2019, recruited 71 children and adolescents with autoimmune thyroiditis and thyroid antibodies (anti-TPO and anti-TG) >60IU/mL. Subjects were randomized to 200 mcg l-selenomethionine (SeMet) or placebo daily for six months. The SeMet group had a significantly greater reduction in anti-TG levels compared to the placebo group. References: Kyrgios, I., …
This preclincal study published in 2021, assessed the pharmacokinetics of long term selenomethionine supplementation (200 mcg over 32 months). Results indicated that total selenium content was 80% higher with supplementation. As expected, the Se mass of most pools increased with SeMet supplementation, because SeMet is incorporated into proteins in place of methionine. References: Patterson, B. …
